专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090162869A1 MEMBRANE MOLECULE EXPRESSED SPECIFICALLY IN ACTIVATED PLASMACYTOID DENDRITIC CELL 审中-公开
标题翻译：活化的PLASMACYTOID DENDRITIC细胞中特异性表达的膜分子
公开(公告)号：US20090162869A1
公开(公告)日：2009-06-25
申请号：US12093501
申请日：2006-11-14
申请人： Hiroshi Watarai , Etsuko Sekine , Masaru Taniguchi
发明人： Hiroshi Watarai , Etsuko Sekine , Masaru Taniguchi
IPC分类号： G01N33/53 , C07K14/46 , C12N15/12 , C12N15/63 , C07K16/18 , C12N1/19 , C12N1/15 , C12N5/10
CPC分类号： C07K14/47 , C07K16/28 , C07K2317/75
摘要： It is an object of the present invention to identify a membrane molecule that is specifically expressed on activated plasmacytoid dendritic cells, for the purpose of preventing or improving affection or disease such as cancer, autoimmune disease, allergy, or infectious disease by regulating the functions of dendritic cells capable of integrating an immune system. The present invention provides a protein having any one of the following amino acid sequences:(a) an amino acid sequence as shown in SEQ ID NO: 2; (b) an amino acid sequence, which comprises a deletion, substitution, insertion and/or addition of one or several amino acid residues with respect to the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells; and (c) an amino acid sequence, which has homology of 80% or more with the amino acid sequence as shown in SEQ ID NO: 2, and which is capable of regulating the functions of dendritic cells.
摘要翻译：本发明的目的是鉴定在激活的浆细胞样树突状细胞上特异性表达的膜分子，以通过调节功能来预防或改善感染或疾病如癌症，自身免疫性疾病，变态反应或感染性疾病能够整合免疫系统的树突状细胞。本发明提供具有以下氨基酸序列之一的蛋白质：（a）SEQ ID NO：2所示的氨基酸序列; （b）氨基酸序列，其包含相对于SEQ ID NO：2所示的氨基酸序列的一个或几个氨基酸残基的缺失，取代，插入和/或添加，并且其能够调节树突细胞的功能; 和（c）氨基酸序列，与SEQ ID NO：2所示的氨基酸序列具有80％以上的同源性，能够调节树突细胞的功能。

2. 发明授权

US10813950B2 Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα, and banking of NKT cells derived from said cells 有权
公开(公告)号：US10813950B2
公开(公告)日：2020-10-27
申请号：US13991059
申请日：2011-12-02
申请人： Masaru Taniguchi , Haruhiko Koseki , Hiroshi Watarai , Shin-ichiro Fujii
发明人： Masaru Taniguchi , Haruhiko Koseki , Hiroshi Watarai , Shin-ichiro Fujii
IPC分类号： A61K35/17 , C12N5/0783 , C07K14/725 , A61K45/06 , A61K31/7028 , C12N15/85
摘要： The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.

3. 发明申请

US20100062990A1 NOVEL PSEUDOGLYCOLIPID AND USE THEREOF 有权
标题翻译：新的PSEUDOGLYCOLIPID及其使用
公开(公告)号：US20100062990A1
公开(公告)日：2010-03-11
申请号：US12528232
申请日：2008-02-22
申请人： Takuya Tashiro , Kenji Mori , Ken-ichi Fuhshuku , Masaru Taniguchi , Ryusuke Nakagawa , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Ken-ichi Fuhshuku , Masaru Taniguchi , Ryusuke Nakagawa , Hiroshi Watarai
IPC分类号： A61K31/7028 , C07H15/00 , A61P35/00
CPC分类号： C07C235/08 , C07C233/18 , C07C233/36 , C07C323/41 , C07C2601/14
摘要： The invention provides a pseudoglycolipid effective for cancer treatment and the like and a novel synthesis intermediate therefor, as well as a medicament containing the pseudoglycolipid and the like. The inventive compound is represented by the formula (1), or a salt thereof, wherein each symbol is as defined in the specification.
摘要翻译：本发明提供了对癌症治疗等有效的假性糖脂及其中间体的新型合成物，以及含有假糖脂等的药物。本发明化合物由式（1）表示，或其盐，其中每个符号如说明书中所定义。

4. 发明授权

US08551959B2 Glycolipid and use thereof 有权
标题翻译：糖脂及其用途
公开(公告)号：US08551959B2
公开(公告)日：2013-10-08
申请号：US12934515
申请日：2009-03-25
申请人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Ryusuke Nakagawa , Masaru Taniguchi , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Ryusuke Nakagawa , Masaru Taniguchi , Hiroshi Watarai
IPC分类号： A01N43/04 , A61K31/70 , A61K39/00 , C07H15/00 , C07H19/00
CPC分类号： C07H15/04
摘要： The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof
摘要翻译：本发明提供了对癌症治疗等有效的糖脂及其合成中间体，以及含有糖脂等的药物。糖脂由式（1）表示或其盐

5. 发明申请

US20130005669A1 NOVEL SYNTHETIC GLYCOLIPID AND USE THEREOF 有权
标题翻译：新型合成甘油脂及其用途
公开(公告)号：US20130005669A1
公开(公告)日：2013-01-03
申请号：US13577159
申请日：2011-02-04
申请人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Masaru Taniguchi , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Masaru Taniguchi , Hiroshi Watarai
IPC分类号： A61K31/7028 , A61P35/00 , C07H15/203 , A61P31/00 , C07H1/00 , C07H15/04 , C12N5/0783
CPC分类号： C07H15/04 , A61K31/7032
摘要： A compound represented by the following formula (1): wherein R1 is an aldopyranose residue wherein the 6-hydroxyl group is optionally alkylated, R2 is a C1-26 hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom or a C1-26 hydrocarbon group optionally having substituent(s), R4 is a C1-21 hydrocarbon group optionally having substituent(s), X is an oxygen atom or —CH2—, and Y is —CH2—, —CH(OH)— or —CH═CH—, or a salt thereof is useful for the prophylaxis or treatment of cancer or infection, since it can preferentially induce production of IFN-γ of NKT cells.
摘要翻译：由下式（1）表示的化合物：其中R1是吡喃葡萄糖残基，其中6-羟基任选被烷基化，R 2是任选具有取代基的C 1-26烃基，R 3是氢原子或C 1 -26任选具有取代基的烃基，R4是任选具有取代基的C 1-12烃基，X是氧原子或-CH 2 - ，Y是-CH 2 - ， - CH（OH） - 或 -CH = CH-或其盐可用于预防或治疗癌症或感染，因为其可优先诱导NKT细胞的IFN-γ的产生。

6. 发明申请

US20110224158A1 ESTERIFIED ALPHA-GALACTOSYLCERAMIDE 有权
标题翻译：已确定的ALPHA-GALACTOSYLCERAMIDE
公开(公告)号：US20110224158A1
公开(公告)日：2011-09-15
申请号：US13063647
申请日：2009-09-11
申请人： Masao Shiozaki , Takuya Tashiro , Kenji Mori , Ryusuke Nakagawa , Hiroshi Watarai , Masaru Taniguchi
发明人： Masao Shiozaki , Takuya Tashiro , Kenji Mori , Ryusuke Nakagawa , Hiroshi Watarai , Masaru Taniguchi
IPC分类号： A61K31/7048 , C07H15/26 , C07H15/02 , A61K31/7028 , A61P37/04 , A61P35/00
CPC分类号： A61K31/7048 , A61K31/7032 , C07H15/06
摘要： The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.
摘要翻译：本发明提供了对癌症治疗有效的酯化α-半乳糖神经酰胺等，以及含有其的药物。具体而言，本发明涉及式（I）表示的化合物：其中，R 1为碳数为1〜30的烃基，R 2为碳数为1〜20的烃基，R 3为氢碳数为1至5的原子或烃基，R 4和R 5相同或不同，各自为氢原子或碳数为1至5的烃基，或R 4和R 5组合形成二价烃碳数为1〜5的基团，并且任选地与相邻的亚乙二氧基或其盐形成环结构。

7. 发明申请

US20110104188A1 NOVEL GLYCOLIPID AND USE THEREOF 有权
标题翻译：新型甘露糖及其用途
公开(公告)号：US20110104188A1
公开(公告)日：2011-05-05
申请号：US12934515
申请日：2009-03-25
申请人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Ryusuke Nakagawa , Masaru Taniguchi , Hiroshi Watarai
发明人： Takuya Tashiro , Kenji Mori , Masao Shiozaki , Ryusuke Nakagawa , Masaru Taniguchi , Hiroshi Watarai
IPC分类号： A61K31/7032 , C07H15/04 , C07H15/10 , A61P35/00 , A61P37/04
CPC分类号： C07H15/04
摘要： The invention provides a glycolipid effective for cancer treatment and the like and a synthetic intermediate therefor, as well as a medicament containing the glycolipid and the like. The glycolipid is represented by the formula (1) or a salt thereof
摘要翻译：本发明提供了对癌症治疗等有效的糖脂及其合成中间体，以及含有糖脂等的药物。糖脂由式（1）表示或其盐

8. 发明授权

US08580751B2 Esterified α-galactosylceramide 有权
标题翻译：酯化的α-半乳糖神经酰胺
公开(公告)号：US08580751B2
公开(公告)日：2013-11-12
申请号：US13063647
申请日：2009-09-11
申请人： Masao Shiozaki , Takuya Tashiro , Kenji Mori , Ryusuke Nakagawa , Hiroshi Watarai , Masaru Taniguchi
发明人： Masao Shiozaki , Takuya Tashiro , Kenji Mori , Ryusuke Nakagawa , Hiroshi Watarai , Masaru Taniguchi
IPC分类号： C07H15/06 , A61K31/70
CPC分类号： A61K31/7048 , A61K31/7032 , C07H15/06
摘要： The invention provides esterified α-galactosylceramides effective for cancer treatment and the like, and a medicament containing same. In particular, the invention relates to a compound represented by the formula (I): wherein R1 is a hydrocarbon group having a carbon number of 1 to 30, R2 is a hydrocarbon group having a carbon number of 1 to 20, R3 is a hydrogen atom or hydrocarbon group having a carbon number of 1 to 5, R4 and R5 are the same or different and each is a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 5, or R4 and R5 in combination form a divalent hydrocarbon group having a carbon number of 1 to 5, and optionally form a ring structure together with the adjacent ethylenedioxy, or a salt thereof.
摘要翻译：本发明提供了对癌症治疗有效的酯化的α-半乳糖神经酰胺等，以及含有它们的药物。具体而言，本发明涉及式（I）表示的化合物：其中，R 1为碳数为1〜30的烃基，R 2为碳数为1〜20的烃基，R 3为氢碳数为1至5的原子或烃基，R 4和R 5相同或不同，各自为氢原子或碳数为1至5的烃基，或R 4和R 5组合形成二价烃碳数为1〜5的基团，并且任选地与相邻的亚乙二氧基或其盐形成环结构。

9. 发明申请

US20130295142A1 IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH ALPHA CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V-ALPHA-J-ALPHA, AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS 审中-公开
标题翻译：使用ALLO-NKT细胞的免疫疗法，其中T细胞受体（TCR）基因的免疫应答细胞已经被重新分化为V-ALPHA-J-ALPHA，以及从固体细胞衍生的NKT细胞的储存
公开(公告)号：US20130295142A1
公开(公告)日：2013-11-07
申请号：US13991059
申请日：2011-12-02
申请人： Masaru Taniguchi , Haruhiko Koseki , Hiroshi Watarai , Shin-ichiro Fujii
发明人： Masaru Taniguchi , Haruhiko Koseki , Hiroshi Watarai , Shin-ichiro Fujii
IPC分类号： A61K35/14 , C12N15/85 , A61K31/7028
摘要： The present invention provides an agent for an immunocyte therapy, comprising an NKT cell obtained by differentiating in vitro a cell having the α-chain region of the T cell receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, wherein an administration subject is an allogenic individual having MHC gene loci including at least one locus having a genotype different from that of the NKT cell. In addition, the present invention provides a bank of a human cell or an NKT cell derived from said cell, wherein the α-chain region of a T cell receptor (TCR) gene has been rearranged to uniform Vα-Jα. The agent and cell bank of the present invention are useful for the prophylaxis and/or treatment of cancer, infection, an allergic disease or an autoimmune disease.
摘要翻译：本发明提供了一种用于免疫细胞治疗的药剂，其包含NKT细胞，所述NKT细胞通过体外将具有T细胞受体基因的α链区域的细胞以NKT细胞受体特异性方式重排为均匀的Valpha-Jalpha获得，其中给药对象是具有MHC基因座的同种异体个体，其包含至少一个具有与NKT细胞基因型不同的基因座。此外，本发明提供了一种人源细胞或源自所述细胞的NKT细胞，其中T细胞受体（TCR）基因的α链区域被重新排列成均匀的Valpha-Jalpha。本发明的药剂和细胞库可用于预防和/或治疗癌症，感染，过敏性疾病或自身免疫性疾病。

10. 发明申请

US20110236362A1 NKT CELL-DERIVED iPS CELLS AND NKT CELLS DERIVED THEREFROM 有权
标题翻译： NKT细胞衍生的iPS细胞和NKT细胞衍生
公开(公告)号：US20110236362A1
公开(公告)日：2011-09-29
申请号：US13062453
申请日：2009-09-08
申请人： Hiroshi Watarai , Haruhiko Koseki , Masaru Taniguchi , Shin-ichiro Fujii
发明人： Hiroshi Watarai , Haruhiko Koseki , Masaru Taniguchi , Shin-ichiro Fujii
IPC分类号： A61K35/12 , C12N5/0783 , C12N15/85 , C12N5/071 , A61P35/00 , A61P31/00 , A61P37/08
CPC分类号： A61K31/7036 , A61K35/12 , C12N5/0646 , C12N5/0696 , C12N2501/23 , C12N2501/2302 , C12N2501/2307 , C12N2501/2315 , C12N2501/26 , C12N2501/42 , C12N2501/60 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/606 , C12N2506/11 , C12N2506/45
摘要： Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination.
摘要翻译：提供衍生自体细胞如NKT细胞的iPS细胞，其具有T细胞抗原受体基因的α链区域以NKT细胞受体特异性方式重排为均匀的Vα-Jα，从iPS分化的NKT细胞细胞，其制备方法以及使用从iPS细胞分化的细胞制备的免疫细胞治疗剂。还提供了将具有重排为T细胞抗原受体基因的α-链区域的体细胞例如NKT细胞与NKT-TCR（NKT-iPS细胞）重排的TCRα的iPS细胞重排为均匀的Vα -Jα以NKT细胞受体特异性方式，具有核重编程因子，通过离体iPS细胞（iPS-NKT细胞）分化获得的分离的NKT细胞，产生CD4 / CD8-双重阳性NKT细胞的方法（DP-NKT 细胞）和来自NKT-iPS细胞的成熟NKT细胞，通过改变饲养细胞和/或细胞因子的组合，扩增iPS-NKT细胞的方法和包含用α-半乳糖基神经酰胺（α）活化的NKT细胞的NKT细胞细胞治疗剂 -GalCer）或iPS-NKT细胞和α-GalCer组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式